Minocycline Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:413871574
Tradename:Minocin, Amzeeq, others
Dailymedid:Minocycline
Pregnancy Au:D
Pregnancy Au Comment:[1]
Routes Of Administration:By mouth, intravenous, topical
Atc Prefix:J01
Atc Suffix:AA08
Atc Supplemental:,
Legal Au:S4
Legal Us:Rx-only
Legal Us Comment:[2]
Bioavailability:90–100%
Protein Bound:70–75%[3]
Metabolism:Liver
Elimination Half-Life:14–22 (11–26) hours
Excretion:Mostly fecal, 10–15% renal
Cas Number:10118-90-8
Pubchem:54675783
Drugbank:DB01017
Chemspiderid:16735907
Unii:FYY3R43WGO
Kegg:D05045
Chebi:50694
Chembl:1434
Iupac Name:(2E,4S,4aR,5aS,12aR)-2-(Amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6- tetrahydro-4H-tetracene-1,3,12-trione[4]
C:23
H:27
N:3
O:7
Smiles:CN(C)c1ccc(c2c1C[C@H]3C[C@H]4[C@@H](C(=C(C(=O)[C@]4(C(=C3C2=O)O)O)C(=O)N)O)N(C)C)O
Stdinchi:1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
Stdinchikey:DYKFCLLONBREIL-KVUCHLLUSA-N
Solubility:Low
Specific Rotation:
25
[\alpha]
D
= −166°

Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic medication used to treat a number of bacterial infections such as some occurring in certain forms of pneumonia. It is generally (but not always) less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.[5] It is taken by mouth or applied to the skin.[6] [7]

Common side effects include nausea, diarrhea, dizziness, allergic reactions, and kidney problems.[6] Serious side effects may include anaphylaxis, a lupus-like syndrome, and easy sunburning.[6] Use in the later part of pregnancy may harm the baby and safety during breastfeeding is unclear.[8] It works by decreasing a bacterium's ability to make protein thus stopping its growth.[6]

Minocycline was patented in 1961 and came into commercial use in 1971.[9] It is available as a generic medication.[5] [10] In 2021, it was the 229th most commonly prescribed medication in the United States, with more than 1million prescriptions.[11] [12]

Medical uses

Acne

Minocycline is indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in people nine years of age and older.[13]

Minocycline and doxycycline are frequently used for the treatment of acne vulgaris.[14] [15] Both of these closely related antibiotics have similar levels of efficacy, although doxycycline has a slightly lower risk of adverse side effects.[16] Historically, minocycline has been an effective treatment for acne vulgaris.[17] However, acne that is caused by antibiotic-resistant bacteria is a growing problem in many countries.[18] In Europe and North America, a number of people with acne no longer respond well to treatment with tetracycline family antibiotics because their acne symptoms are caused by bacteria (primarily Cutibacterium acnes) that are resistant to these antibiotics. In order to reduce resistance rates as well as increase the effectiveness of treatment, oral antibiotics should be generally combined with topical acne creams such as benzoyl peroxide or a retinoid (tretinoin, adapalene, etc.).[19]

Infections

Minocycline is also used for other skin infections such as methicillin-resistant Staphylococcus aureus.[20]

Although minocycline's broader spectrum of activity, compared with other members of the group, includes activity against Neisseria meningitidis,[21] its use for prophylaxis is no longer recommended because of side effects (dizziness and vertigo).

It may be used to treat certain strains of methicillin-resistant S. aureus infection and a disease caused by drug-resistant Acinetobacter spp.[22]

A list of uses includes:

Other

Both minocycline and doxycycline have shown effectiveness in asthma due to immune-suppressing effects.[26] Minocycline and doxycycline have modest effectiveness in treating rheumatoid arthritis.[27] However, the 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis does not include minocycline.[28] Recent research indicate that centrally infused minocycline attenuates brain microglial activation, neuroinflammation and sympathetic activation during pulmonary hypertension.[29]

Contraindications

The drug is contraindicated in people with known hypersensitivity to tetracycline antibiotics, as there is complete cross sensitivity in this group. It is also contraindicated in people with severe liver impairment and after the 16th week of pregnancy.

Side effects

See also: List of dental abnormalities associated with cutaneous conditions.

Minocycline may cause upset stomach, diarrhea, dizziness, unsteadiness, drowsiness, mouth sores, migraines, and vomiting. It increases sensitivity to sunlight, and may affect the quality of sleep and rarely causes sleep disorders.[30] It has also been linked to cases of lupus.[31] Prolonged use of minocycline can lead to blue-gray staining of skin, fingernails, and scar tissue. This staining is not permanent, but can take a very long time for the skin color to return to normal; however, a muddy brown skin color in sun-exposed areas is usually permanent.[32] Permanent blue discoloration of gums or teeth discoloration may also occur. Rare but serious side effects include fever, yellowing of the eyes or skin, stomach pain, sore throat, vision changes, and mental changes, including depersonalization.[33] [34]

Occasionally, minocycline therapy may result in autoimmune disorders such as drug-related lupus and autoimmune hepatitis, which usually occurs in men who also developed minocycline-induced lupus; however, women are more likely to develop minocycline-induced lupus. Significant or complete recovery occurs in most people who develop minocycline-induced autoimmune problems within a period of a few weeks to a year of cessation of minocycline therapy. Autoimmune problems emerge during chronic therapy, but can sometimes occur after only short courses of a couple of weeks of therapy.[35] [36] Drug reaction with eosinophilia and systemic symptoms syndrome can occur during the first few weeks of therapy with minocycline.[36]

Minocycline, but not other tetracyclines, can cause vestibular disturbances with dizziness, ataxia, vertigo, and tinnitus. These effects are thought to be related to minocycline's greater penetration into the central nervous system. Vestibular side effects are much more common in women than in men, occurring in 50 to 70% of women receiving minocycline. As a result of the frequency of this bothersome side effect, minocycline is rarely used in female patients.[37] Minocycline's vestibular side effects typically resolve after discontinuation of the drug.[38] [39] [40] [41]

Symptoms of an allergic reaction include rash, itching, swelling, severe dizziness, and trouble breathing. Minocycline has also been reported to very rarely cause idiopathic intracranial hypertension (pseudotumor cerebri),[42] a side effect also more common in female patients, potentially leading to permanent vision damage if not recognized early and treated.[43]

Contrary to most other tetracycline antibiotics (doxycycline excluded), minocycline may be used in those with kidney disease, but may aggravate systemic lupus erythematosus.[44] It may also trigger or unmask autoimmune hepatitis.[45]

Minocycline can cause the rare condition of secondary intracranial hypertension, which has initial symptoms of headache, visual disturbances, dizziness, vomiting, and confusion.[46] Brain swelling and rheumatoid arthritis are rare side effects of minocycline in some people.[47]

Minocycline, like most tetracyclines, becomes dangerous past its expiration date.[48] While most prescription drugs lose potency after their expiration dates, tetracyclines are known to become toxic over time. Expired tetracyclines can cause serious damage to the kidney due to the formation of a degradation product, anhydro-4-epitetracycline.[48] Minocycline's absorption is impaired if taken at the same time of day as calcium or iron supplements. Unlike some of the other tetracycline group antibiotics, it can be taken with calcium-rich foods such as milk, although this does reduce the absorption slightly.[49]

Minocycline, like other tetracyclines, is associated with esophageal irritation and ulceration if insufficient fluids are taken with the drug before sleep.[50]

A 2007 study suggested that minocycline harms amyotrophic lateral sclerosis patients. Patients on minocycline declined more rapidly than those on placebo. The mechanism of this side effect is unknown, although a hypothesis is that the drug exacerbated an autoimmune component of the primary disease. The effect does not seem to be dose-dependent because the patients on high doses did not do worse than those on the low doses.[51]

The use of minocycline in acne vulgaris has been associated with skin and gut dysbiosis (see antibiotic misuse).[52]

Interactions

The combination of minocycline with dairy, antacids, calcium and magnesium supplements, iron products, laxatives containing magnesium, or bile acid sequestrants may decrease minocycline's effectiveness by forming chelates. Combining it with isotretinoin, acitretin or other retinoids can increase the risk for intracranial hypertension. Minocycline significantly reduces concentrations of the anti-HIV drug atazanavir in the body.[53]

Pharmacology

Pharmacokinetics

Minocycline is quickly and nearly completely absorbed from the upper part of the small intestine. Taking it together with food, including milk, has no relevant influence on resorption. It reaches highest blood plasma concentrations after one to two hours and has a plasma protein binding of 70–75%. The substance penetrates into almost all tissues; very high concentrations are found in the gallbladder and liver. It crosses the blood–brain barrier better than doxycycline and other tetracyclines, reaching therapeutically relevant concentrations in the cerebrospinal fluid and also in inflamed meninges.[54]

Minocycline is inactivated by metabolization in the liver to about 50%. The rest is predominantly excreted into the gut (in part via the gallbladder, in part directly from blood vessels) and eliminated via the feces. About 10–15% are eliminated via the kidneys. The biological half-life is 14–22 (11–26) hours in healthy people, up to 30 hours in those with kidney failure, and significantly longer in those with liver disease.

Chemistry

The drug is used in form of minocycline hydrochloride dihydrate, which is sparingly soluble in water and slightly soluble in ethanol. Minocycline reacts acidic in aqueous solution.

History

Minocycline was patented in 1961 and came into commercial use in 1971. A topical foam for treatment of acne was approved in 2019.

Society and culture

Brand names

It is available as a generic medication.[5]

Research

Early research has found a tentative benefit from minocycline in schizophrenia,[56] with several trials underway.[57] A 2014 meta-analysis found minocycline may reduce negative and total symptom scores and was well tolerated.[58]

Research is examining the possible neuroprotective and anti-inflammatory effects of minocycline against the progression of a group of neurodegenerative disorders including multiple sclerosis, rheumatoid arthritis, Huntington's disease, and Parkinson's disease.[59] [60] [61] [62] As mentioned above, minocycline harms ALS patients.

Minocycline is also known to indirectly inhibit inducible nitric oxide synthase.[63]

A trial found no difference between minocycline and placebo in people with Alzheimers' disease.[64] Minocycline also has been used as a "last-ditch" treatment for toxoplasmosis in AIDS patients.[65] Minocycline is somewhat neuroprotective in mouse models of Huntington's disease.[66]

A 2007 study reported the impact of the antibiotic minocycline on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in 40 MS patients over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment relapse rate in the patient group prior to treatment (1.3/year pre-enrollment; 1.2/year during a three-month baseline period), no relapses occurred between months 6 and 24 on minocycline. Also, despite significant MRI disease-activity pretreatment (19/40 scans had gadolinium-enhancing activity during a three-month run-in), the only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline. Levels of interleukin-12 (IL-12), which at high levels might antagonize the proinflammatory IL-12 receptor, were elevated over 18 months of treatment, as were levels of soluble vascular cell adhesion molecule-1 (VCAM-1). The activity of matrix metalloproteinase-9 was decreased by treatment. Clinical and MRI outcomes in this study were supported by systemic immunological changes and call for further investigation of minocycline in MS.[67] [68] [69]

Minocycline has been studied for treatment-resistant depression. According to a systematic review based on four clinical trials, "There is no significant difference with minocycline compared to placebo for depression not responding to first-line antidepressant therapy."[70]

In ongoing research and trial, minocycline demonstrated efficacy and seems a promising neuroprotective agent in acute stroke patients, especially in AIS subgroup. Further RCTs are needed to evaluate the efficacy and safety of minocycline among ICH patients.[71]

Several preclinical studies (in vitro cell cultures and animal models) suggest that minocycline may have otoprotective benefits. Animal models indicate it could potentially reduce noise-induced and blast-induced hearing loss, possibly by protecting hair cells and mitigating inflammation.[72] [73] In vitro and animal studies also show minocycline may help decrease ototoxicity from certain drugs like gentamicin,[74] neomycin,[75] and cisplatin.[76] [77]

Some early studies suggest that minocycline may be beneficial as an add-on treatment for moderate-to-severe obsessive-compulsive disorder (OCD) when used with an SSRI.[78] [79]

Data from cellular and animal models

Notes and References

  1. Web site: Minocycline Use During Pregnancy . Drugs.com . 4 December 2018 . 16 May 2020.
  2. Web site: Minocin- minocycline hydrochloride injection . DailyMed . 28 July 2021 . 19 February 2023.
  3. Book: Arzneistoff-Profile. Dinnendahl V, Fricke U . Govi Pharmazeutischer Verlag. Eschborn, Germany. 2010. 24. 7. Minocyclin . 978-3-7741-9846-3 . de.
  4. Web site: Minocycline. go.drugbank.com.
  5. Book: British national formulary : BNF 76. 2018. Pharmaceutical Press. 9780857113382. 556. 76.
  6. Web site: Minocycline Hydrochloride Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 23 March 2019 .
  7. Web site: Amzeeq- minocycline aerosol, foam . DailyMed . 25 January 2023 . 18 February 2023.
  8. Web site: Minocycline Use During Pregnancy . Drugs.com . 3 March 2019 . en.
  9. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery. 2006. John Wiley & Sons. 9783527607495. 489. en.
  10. Web site: First Generic Drug Approvals . U.S. Food and Drug Administration . 17 October 2022 . 28 November 2022.
  11. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  12. Web site: Minocycline - Drug Usage Statistics . ClinCalc . 14 January 2024.
  13. Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, Freeman EE, Keri JE, Stein Gold LF, Tan JK, Tollefson MM, Weiss JS, Wu PA, Zaenglein AL, Han JM, Barbieri JS . Guidelines of care for the management of acne vulgaris . J Am Acad Dermatol . 90 . 5 . 1006.e1–1006.e30 . May 2024 . 38300170 . 10.1016/j.jaad.2023.12.017.
  14. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, Thiboutot DM, Van Voorhees AS, Beutner KA, Sieck CK, Bhushan R . 6 . Guidelines of care for acne vulgaris management . Journal of the American Academy of Dermatology . 56 . 4 . 651–663 . April 2007 . 17276540 . 10.1016/j.jaad.2006.08.048 .
  15. Web site: Minocycline, Doxycycline and Acne Vulgaris . ScienceOfAcne.com . 7 August 2012. https://web.archive.org/web/20120807133359/http://scienceofacne.com:80/doxycycline-and-minocycline. 7 August 2012.
  16. Kircik LH . Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications . Journal of Drugs in Dermatology . 9 . 11 . 1407–1411 . November 2010 . 21061764 .
  17. Hubbell CG, Hobbs ER, Rist T, White JW . Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris . Archives of Dermatology . 118 . 12 . 989–992 . December 1982 . 6216858 . 10.1001/archderm.1982.01650240033017 .
  18. Eady EA, Gloor M, Leyden JJ . Propionibacterium acnes resistance: a worldwide problem . Dermatology . 206 . 1 . 54–56 . 2003 . 12566805 . 10.1159/000067822 . 6111436 .
  19. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Peréz Del Pulgar JI, Rollman O, Török L, Eady EA, Cove JH . 6 . Antibiotic-resistant acne: lessons from Europe . The British Journal of Dermatology . 148 . 3 . 467–478 . March 2003 . 12653738 . 10.1046/j.1365-2133.2003.05067.x . 0706.4406 . 20838517 . 10454/3069 .
  20. Rogers RL, Perkins J . Skin and soft tissue infections . Primary Care . 33 . 3 . 697–710 . September 2006 . 17088156 . 10.1016/j.pop.2006.06.005 .
  21. Fraser A, Gafter-Gvili A, Paul M, Leibovici L . Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials . European Journal of Clinical Microbiology & Infectious Diseases . 24 . 3 . 172–181 . March 2005 . 15782277 . 10.1007/s10096-005-1297-7 . 1259483 .
  22. Bishburg E, Bishburg K . Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii . International Journal of Antimicrobial Agents . 34 . 5 . 395–401 . November 2009 . 19665876 . 10.1016/j.ijantimicag.2009.06.021 .
  23. Copeland KF, Brooks JI . A novel use for an old drug: the potential for minocycline as anti-HIV adjuvant therapy . The Journal of Infectious Diseases . 201 . 8 . 1115–1117 . April 2010 . 20205572 . 10.1086/651278 . free .
  24. Mungroo MR, Khan NA, Siddiqui R . Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options . Microbial Pathogenesis . 149 . 104475 . December 2020 . 32931893 . 10.1016/j.micpath.2020.104475 . 221748544 .
  25. U.S. National Library of Medicine (11 December 2009) 'Perioral dermatitis'. Retrieved 7 August 2010.
  26. Joks R, Durkin HG . Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs . Pharmacological Research . 64 . 6 . 602–609 . December 2011 . 21501686 . 10.1016/j.phrs.2011.04.001 .
  27. Greenwald RA . The road forward: the scientific basis for tetracycline treatment of arthritic disorders . Pharmacological Research . 64 . 6 . 610–613 . December 2011 . 21723947 . 10.1016/j.phrs.2011.06.010 .
  28. Web site: Clinical Practice Guidelines: Rheumatoid Arthritis. American College of Rheumatology. 13 May 2017.
  29. Sharma RK, Oliveira AC, Kim S, Rigatto K, Zubcevic J, Rathinasabapathy A, Kumar A, Lebowitz JJ, Khoshbouei H, Lobaton G, Aquino V, Richards EM, Katovich MJ, Shenoy V, Raizada MK . 6 . Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension . Hypertension . 71 . 6 . 1156–1163 . June 2018 . 29712738 . 5945302 . 10.1161/HYPERTENSIONAHA.118.10934 .
  30. Nonaka K, Nakazawa Y, Kotorii T . Effects of antibiotics, minocycline and ampicillin, on human sleep . Brain Research . 288 . 1–2 . 253–259 . December 1983 . 6661620 . 10.1016/0006-8993(83)90101-4 . 22726747 .
  31. News: MedlinePlus Drug Information: Minocycline Oral .
  32. Geria AN, Tajirian AL, Kihiczak G, Schwartz RA . Minocycline-induced skin pigmentation: an update . Acta Dermatovenerologica Croatica . 17 . 2 . 123–126 . 2009 . 19595269 .
  33. Web site: minocycline (Dynacin): Antibiotic Side Effects & Dosage. MedicineNet.
  34. Cohen PR . Medication-associated depersonalization symptoms: report of transient depersonalization symptoms induced by minocycline . Southern Medical Journal . 97 . 1 . 70–73 . January 2004 . 14746427 . 10.1097/01.SMJ.0000083857.98870.98 . 27125601 .
  35. Mongey AB, Hess EV . Drug insight: autoimmune effects of medications-what's new? . Nature Clinical Practice. Rheumatology . 4 . 3 . 136–144 . March 2008 . 18200008 . 10.1038/ncprheum0708 . 205340777 .
  36. Ochsendorf F . Minocycline in acne vulgaris: benefits and risks . American Journal of Clinical Dermatology . 11 . 5 . 327–341 . 2010 . 20642295 . 10.2165/11319280-000000000-00000 . 24501240 .
  37. Book: Sweet RL, Gibbs RS . Infectious Diseases of the Female Genital Tract . 4th . 2001 . Lippincott Williams & Wilkins . 635.
  38. Book: Bauman, Neil . Ototoxic Drugs Exposed . 2010 . 978-1-935939-00-9 . 3 . 435–436 . Integrity First Publications . You can develop symptoms of ototoxicity after only one or two doses. These symptoms normally disappear a day or two after you stop taking this drug..
  39. Web site: Minocycline Side Effects: Common, Severe, Long Term . Drugs.com . 27 December 2023 . 16 January 2024 . https://web.archive.org/web/20240116091026/https://www.drugs.com/sfx/minocycline-side-effects.html . 16 January 2024 . Headache, dizziness, vertigo, and ataxia have been reported. These side effects were reversible within 3 to 48 hours of stopping therapy and occurred less often with low doses..
  40. Williams DN, Laughlin LW, Lee YH . Minocycline: Possible vestibular side-effects . Lancet . 2 . 7883 . 744–6 . September 1974 . 4143012 . 10.1016/s0140-6736(74)90941-6 . 17 (89%) of 19 persons taking minocycline for the treatment of bacteriuria or for prophylaxis of meningococcal disease developed nausea, vomiting, weakness, ataxia, vertigo, or dizziness, 24-48 hours after the initiation of therapy. These symptoms usually occurred in combination, were often acute and severe, and disappeared shortly after therapy was discontinued..
  41. Jacobson JA, Daniel B . Vestibular reactions associated with minocycline . Antimicrobial Agents and Chemotherapy . 8 . 4 . 453–6 . October 1975 . 1081373 . 429369 . 10.1128/AAC.8.4.453.
  42. Friedman DI . Medication-induced intracranial hypertension in dermatology . American Journal of Clinical Dermatology . 6 . 1 . 29–37 . 2005 . 15675888 . 10.2165/00128071-200506010-00004 . 28395784 .
  43. Mechrgui M, Kanani S . The Ophthalmic Side Effects of Topiramate: A Review . Cureus . 14 . 8 . e28513 . August 2022 . 36059357 . 9420653 . 10.7759/cureus.28513 . free .
  44. Gough A, Chapman S, Wagstaff K, Emery P, Elias E . Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome . BMJ . 312 . 7024 . 169–172 . January 1996 . 8563540 . 2349841 . 10.1136/bmj.312.7024.169 .
  45. Krawitt EL . Autoimmune hepatitis . The New England Journal of Medicine . 354 . 1 . 54–66 . January 2006 . 16394302 . 10.1056/NEJMra050408 . 5361674 .
  46. Friedman DI . Medication-induced intracranial hypertension in dermatology . American Journal of Clinical Dermatology . 6 . 1 . 29–37 . 2005 . 15675888 . 10.2165/00128071-200506010-00004 . Springer Science and Business Media LLC . 28395784 .
  47. Lefebvre N, Forestier E, Farhi D, Mahsa MZ, Remy V, Lesens O, Christmann D, Hansmann Y . 6 . Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: a case report . Journal of Medical Case Reports . 1 . 22 . May 2007 . 17511865 . 1884162 . 10.1186/1752-1947-1-22 . vanc . free .
  48. "Principles and methods for the assessment of nephrotoxicity associated with exposure to chemicals". Environmental health criteria: 119. World Health Organization (WHO). . ISSN 0250-863X. 1991
  49. Book: Drug Interactions in Infectious Diseases . Piscitelli SC, Rodvold K . 2005 . Humana Press . 978-1-58829-455-5 . registration .
  50. Drugs.com 'Minocycline Disease Interactions'. Retrieved 12 February 2017.
  51. Couzin J . Clinical research. ALS trial raises questions about promising drug . Science . 318 . 5854 . 1227 . November 2007 . 18033854 . 10.1126/science.318.5854.1227a . 72187805 .
  52. Thompson KG, Rainer BM, Antonescu C, Florea L, Mongodin EF, Kang S, Chien AL . Minocycline and Its Impact on Microbial Dysbiosis in the Skin and Gastrointestinal Tract of Acne Patients . Annals of Dermatology . 32 . 1 . 21–30 . February 2020 . 33911705 . 7992645 . 10.5021/ad.2020.32.1.21 . free .
  53. Web site: Minocycline. mediQ. 6 August 2020.
  54. Book: Austria-Codex. Haberfeld H . Minostad 50 mg-Kapseln. Österreichischer Apothekerverlag. Vienna. 2020. de.
  55. Web site: How ARESTIN is supplied and dosed. OraPharma, Inc.. 1 January 2010. 9 January 2010. https://web.archive.org/web/20100109103746/http://www.arestin.com/for-professionals-easy-administer.jsp. dead.
  56. Dean OM, Data-Franco J, Giorlando F, Berk M . Minocycline: therapeutic potential in psychiatry . CNS Drugs . 26 . 5 . 391–401 . May 2012 . 22486246 . 10.2165/11632000-000000000-00000 .
  57. Will Antibiotic Fulfill Its Psychosis-Fighting Promise?. Psychiatric News. 47. 16. 10. Arehart-Treichel J . 17 August 2012. 10.1176/pn.47.16.psychnews_47_16_10-a.
  58. Oya K, Kishi T, Iwata N . Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials . Human Psychopharmacology . 29 . 5 . 483–491 . September 2014 . 25087702 . 10.1002/hup.2426 . 3564390 .
  59. Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson's Disease . National Institute of Health . 23 February 2006 .
  60. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM . 6 . Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease . Nature Medicine . 6 . 7 . 797–801 . July 2000 . 10888929 . 10.1038/77528 . 22681391 .
  61. Tikka TM, Koistinaho JE . Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia . Journal of Immunology . 166 . 12 . 7527–7533 . June 2001 . 11390507 . 10.4049/jimmunol.166.12.7527 . free .
  62. Nirmalananthan N, Greensmith L . Amyotrophic lateral sclerosis: recent advances and future therapies . Current Opinion in Neurology . 18 . 6 . 712–719 . December 2005 . 16280684 . 10.1097/01.wco.0000187248.21103.c5 . 3255995 .
  63. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB . 6 . A novel mechanism of action of tetracyclines: effects on nitric oxide synthases . Proceedings of the National Academy of Sciences of the United States of America . 93 . 24 . 14014–14019 . November 1996 . 8943052 . 19486 . 10.1073/pnas.93.24.14014 . free . 1996PNAS...9314014A .
  64. Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Nilforooshan R, Wilcock G, Gray R . 6 . Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial . JAMA Neurology . 77 . 2 . 164–174 . February 2020 . 31738372 . 6865324 . 10.1001/jamaneurol.2019.3762 . free .
  65. Lacassin F, Schaffo D, Perronne C, Longuet P, Leport C, Vilde JL . Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus . Antimicrobial Agents and Chemotherapy . 39 . 1 . 276–277 . January 1995 . 7695324 . 162527 . 10.1128/AAC.39.1.276 .
  66. Beal MF, Ferrante RJ . Experimental therapeutics in transgenic mouse models of Huntington's disease . Nature Reviews. Neuroscience . 5 . 5 . 373–384 . May 2004 . 15100720 . 10.1038/nrn1386 . 19496441 .
  67. Zemke D, Majid A . The potential of minocycline for neuroprotection in human neurologic disease . Clinical Neuropharmacology . 27 . 6 . 293–298 . 2004 . 15613934 . 10.1097/01.wnf.0000150867.98887.3e . 30431947 .
  68. Maier K, Merkler D, Gerber J, Taheri N, Kuhnert AV, Williams SK, Neusch C, Bähr M, Diem R . 6 . Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation . Neurobiology of Disease . 25 . 3 . 514–525 . March 2007 . 17239606 . 10.1016/j.nbd.2006.10.022 . 39628457 .
  69. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID . Inhibition of autoimmune encephalomyelitis by a tetracycline . Annals of Neurology . 51 . 2 . 215–223 . February 2002 . 11835378 . 10.1002/ana.10092 . 21209994 .
  70. Shamim MA, Manna S, Dwivedi P, Swami MK, Sahoo S, Shukla R, Srivastav S, Thaper K, Saravanan A, Anil A, Varthya SB, Singh S, Shamim MA, Satapathy P, Chattu SK, Chattu VK, Padhi BK, Sah R . 6 . Minocycline in depression not responding to first-line therapy: A systematic review and meta-analysis . Medicine . 102 . 45 . e35937 . November 2023 . 37960804 . 10.1097/MD.0000000000035937 . free . 10637431 .
  71. Malhotra K, Chang JJ, Khunger A, Blacker D, Switzer JA, Goyal N, Hernandez AV, Pasupuleti V, Alexandrov AV, Tsivgoulis G . 6 . Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials . Journal of Neurology . 265 . 8 . 1871–1879 . August 2018 . 29948247 . 10.1007/s00415-018-8935-3 . free . 49431206 . 10757/624615 .
  72. Zhang J, Song YL, Tian KY, Qiu JH . Minocycline attenuates noise-induced hearing loss in rats . Neuroscience Letters . 639 . 31–35 . February 2017 . 28007648 . 10.1016/j.neulet.2016.12.039. 38379616 .
  73. Perumal V, Ravula AR, Shao N, Chandra N . Effect of minocycline and its nano-formulation on central auditory system in blast-induced hearing loss rat model . Journal of Otology . 18 . 1 . 38–48 . January 2023 . 36820161 . 9937842 . 10.1016/j.joto.2022.09.002.
  74. Wei X, Zhao L, Liu J, Dodel RC, Farlow MR, Du Y . Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation . . 131 . 2 . 513–21 . 2005 . 15708492 . 10.1016/j.neuroscience.2004.11.014. 3125930 .
  75. Robinson AM, Vujanovic I, Richter CP . Minocycline protection of neomycin induced hearing loss in gerbils . BioMed Research International . 2015 . 934158 . 2015 . 25950003 . 4407513 . 10.1155/2015/934158. free .
  76. Lee CK, Shin JI, Cho YS . Protective Effect of Minocycline Against Cisplatin-induced Ototoxicity . Clinical and Experimental Otorhinolaryngology . 4 . 2 . 77–82 . June 2011 . 21716954 . 3109331 . 10.3342/ceo.2011.4.2.77.
  77. Du B, Zhang Y, Tang Y, Wang P . Minocycline attenuates ototoxicity and enhances antitumor activity of cisplatin treatment in vitro . Otolaryngology–Head and Neck Surgery . 144 . 5 . 719–25 . May 2011 . 21493367 . 10.1177/0194599810395090. 25994657 .
  78. van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI . Treatment-resistant OCD: Pharmacotherapies in adults . Comprehensive Psychiatry . 120 . 152352 . January 2023 . 36368186 . 10.1016/j.comppsych.2022.152352. 2445/192315 . free .
  79. Panizzutti B, Skvarc D, Lin S, Croce S, Meehan A, Bortolasci CC, Marx W, Walker AJ, Hasebe K, Kavanagh BE, Morris MJ, Mohebbi M, Turner A, Gray L, Berk L, Walder K, Berk M, Dean OM . Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis . International Journal of Molecular Sciences . 24 . 6 . March 2023 . 5250 . 36982324 . 10049047 . 10.3390/ijms24065250. free .
  80. Alano CC, Kauppinen TM, Valls AV, Swanson RA . Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations . Proceedings of the National Academy of Sciences of the United States of America . 103 . 25 . 9685–9690 . June 2006 . 16769901 . 1480467 . 10.1073/pnas.0600554103 . free . 2006PNAS..103.9685A .
  81. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J . Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia . The Journal of Neuroscience . 21 . 8 . 2580–2588 . April 2001 . 11306611 . 6762519 . 10.1523/JNEUROSCI.21-08-02580.2001 .
  82. Web site: minomycin-if . 8 September 2017 . 8 September 2017 . https://web.archive.org/web/20170908112018/http://www.info.pmda.go.jp/go/interview/2/671450_6152005F1052_2_1F.pdf . dead .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Minocycline".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.